Program
icalcaprant
Also written as “Icalcaprant”, “CVL-354” and “ABBV-1354”.
In AbbVie's pipeline, KOR antagonist
. Its studies are mostly in Bipolar Disorder · Depressive Disorder, Major, led by AbbVie.
Furthest: phase 2, since Nov 18, 20246 company-led studies, 2 open or runningNext primary completion: Sep 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 62 open or running | phase 2since Nov 18, 2024 | Nov 17, 2021 | Sep 2027phase 2 · NCT07276997 |
- Named in AbbVie’s own pipeline as
Icalcaprant (ABBV-1354)
, phase 2, as of Jul 30, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 17, 2021First study: phase 1 study in Healthy ParticipantsFirst studyNCT05138653 · 73 enrolled · United States
- Nov 18, 2024Phase 2 study in Bipolar DisorderNCT06696755 · 195 planned · United States
- Dec 4, 20242 phase 1 studies in Healthy VolunteerNCT06722430, NCT06722417
- Oct 17, 2025Phase 1 study in Healthy VolunteerNCT07219017 · 8 enrolled · United States
- Dec 2, 2025Phase 2 study in Depressive Disorder, MajorNCT07276997 · 195 planned · United States
Ahead
- Sep 2027Primary completion: phase 2 study in Depressive Disorder, MajorNCT07276997
- Nov 2027Primary completion: phase 2 study in Bipolar DisorderNCT06696755
TargetBeta
“KOR antagonist”the company's pipeline, read by Claude · source
Other programs on OPRK1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Naltrexonerule | orexigen-therapeutics-inc | phase 4 | 42 |
| nalmefenerule | H. Lundbeck | phase 4 | 20 |
| Nalbuphinerule | Trevi Therapeutics | phase 4 | 20 |
| cebranopadolrule | Tris Pharma | phase 3 | 18 |
| Aticaprantrule | Johnson & Johnson | phase 3 | 13 |
| nalfurafinerule | toray-industries-inc | phase 3 | 9 |
| asimadolinerule | tioga-pharmaceuticals | phase 3 | 6 |
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07276997Depressive Disorder, Major · United States | 2 | Recruiting | Sep 2027 | 195 |
| NCT07219017Healthy Volunteer · United States | 1 | Completed | Dec 9, 2025 | 8 |
| NCT06722430Healthy Volunteer · United States | 1 | Completed | Jan 13, 2025 | 12 |
| NCT06722417Healthy Volunteer · United States | 1 | Completed | Jan 17, 2025 | 16 |
| NCT06696755Bipolar Disorder · United States | 2 | Recruiting | Nov 2027 | 195 |
| NCT05138653Healthy Participants · United States | 1 | Completed | Jan 23, 2023 | 73 |
How it is read
Names in the registry
- “Icalcaprant”, 4 entries
- “CVL-354”, 2 entries
- “ABBV-1354”, 1 entry
Codes read as this program: ABBV1354.
Conditions, from the studies’ own filings
- Bipolar Disorder, 1 study
- Depressive Disorder, Major, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.